197 related articles for article (PubMed ID: 32734613)
1. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
2. Intratumoral IL22-producing cells define immunoevasive subtype muscle-invasive bladder cancer with poor prognosis and superior nivolumab responses.
Zeng H; Liu Z; Wang Z; Zhou Q; Qi Y; Chen Y; Chen L; Zhang P; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Int J Cancer; 2020 Jan; 146(2):542-552. PubMed ID: 31584197
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
4. Latency-associated peptide identifies therapeutically resistant muscle-invasive bladder cancer with poor prognosis.
Ye R; Zeng H; Liu Z; Jin K; Liu C; Yan S; Yu Y; You R; Zhang H; Chang Y; Wang Y; Liu L; Zhu Y; Xu J; Xu L; Wang Z
Cancer Immunol Immunother; 2022 Feb; 71(2):301-310. PubMed ID: 34152439
[TBL] [Abstract][Full Text] [Related]
5. Immune inactivation by VISTA predicts clinical outcome and therapeutic benefit in muscle-invasive bladder cancer.
Li W; Liu Z; Jin K; Shao F; Zeng H; Wang Y; Zhu Y; Xu L; Wang Z; Chang Y; Zhang W
BMC Cancer; 2023 Jul; 23(1):661. PubMed ID: 37452272
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
7. Poor clinical outcomes and immunoevasive contexture in SIRPĪ±
Xu Z; Zeng H; Liu Z; Jin K; Chang Y; Wang Y; Liu L; Zhu Y; Xu L; Wang Z; Guo J; Xu J
Urol Oncol; 2022 Mar; 40(3):109.e11-109.e20. PubMed ID: 34600802
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer.
Xu Y; Zeng H; Jin K; Liu Z; Zhu Y; Xu L; Wang Z; Chang Y; Xu J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338085
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of poor prognosis immunoevasive subtype of muscle-invasive bladder cancer with tumor-infiltrating podoplanin
Zhou Q; Wang Z; Zeng H; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Liu L; Zhu Y; Xu L; Dai B; Guo J; Xia Y; Wang Y; Xu J
Oncoimmunology; 2020 Apr; 9(1):1747333. PubMed ID: 33457092
[TBL] [Abstract][Full Text] [Related]
10. Stromal LAG-3
Zeng H; Zhou Q; Wang Z; Zhang H; Liu Z; Huang Q; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Xu L; Dai B; Guo J; Liu L; Zhu Y; Xu J
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540859
[TBL] [Abstract][Full Text] [Related]
11. Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response.
Qi Y; Chang Y; Wang Z; Chen L; Kong Y; Zhang P; Liu Z; Zhou Q; Chen Y; Wang J; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Y; Xu J; Zhang W
Cancer Immunol Immunother; 2019 Dec; 68(12):2067-2080. PubMed ID: 31720813
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral CCR5
Xiang Z; Zhou Q; Zeng H; Wang Z; Zhang H; Liu Z; Huang Q; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Wang J; Guo J; Xu J
Oncoimmunology; 2020 Aug; 9(1):1802176. PubMed ID: 32923162
[TBL] [Abstract][Full Text] [Related]
13. CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer.
Wang T; Zhou Q; Zeng H; Zhang H; Liu Z; Shao J; Wang Z; Xiong Y; Wang J; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Chang Y; Wang X; Xu J
Cancer Immunol Immunother; 2020 Sep; 69(9):1855-1867. PubMed ID: 32367308
[TBL] [Abstract][Full Text] [Related]
14. Blockade of DC-SIGN
Hu B; Wang Z; Zeng H; Qi Y; Chen Y; Wang T; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Dai B; Guo J; Xu L; Zhang W; Xu J
Cancer Res; 2020 Apr; 80(8):1707-1719. PubMed ID: 32060149
[TBL] [Abstract][Full Text] [Related]
15. Molecular, Immunological, and Clinical Features Associated With Lymphoid Neogenesis in Muscle Invasive Bladder Cancer.
Pagliarulo F; Cheng PF; Brugger L; van Dijk N; van den Heijden M; Levesque MP; Silina K; van den Broek M
Front Immunol; 2021; 12():793992. PubMed ID: 35145509
[TBL] [Abstract][Full Text] [Related]
16. CD19
Jiang Q; Fu Q; Chang Y; Liu Z; Zhang J; Xu L; Zhu Y; Wang Y; Zhang W; Xu J
Cancer Immunol Immunother; 2019 Jan; 68(1):45-56. PubMed ID: 30259082
[TBL] [Abstract][Full Text] [Related]
17. Identification and validation of an excellent prognosis subtype of muscle-invasive bladder cancer patients with intratumoral CXCR5
Huang Q; Zhou Q; Zhang H; Liu Z; Zeng H; Chen Y; Qu Y; Xiong Y; Wang J; Chang Y; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang Z; Bai Q; Zhang W
Oncoimmunology; 2020 Aug; 9(1):1810489. PubMed ID: 32939328
[TBL] [Abstract][Full Text] [Related]
18. An immune relevant signature for predicting prognoses and immunotherapeutic responses in patients with muscle-invasive bladder cancer (MIBC).
Jiang W; Zhu D; Wang C; Zhu Y
Cancer Med; 2020 Apr; 9(8):2774-2790. PubMed ID: 32096345
[TBL] [Abstract][Full Text] [Related]
19. CD103
Jin K; Yu Y; Zeng H; Liu Z; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 Jun; 126(11):1581-1588. PubMed ID: 35165401
[TBL] [Abstract][Full Text] [Related]
20. TIGIT and PD-1 expression atlas predicts response to adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer.
Liu Z; Zeng H; Jin K; Yu Y; You R; Zhang H; Liu C; Su X; Yan S; Chang Y; Liu L; Xu L; Xu J; Zhu Y; Wang Z
Br J Cancer; 2022 May; 126(9):1310-1317. PubMed ID: 35039625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
